VEGFA and glioma: Introduction of A2V, a bispecific antibody to VEGF, and Ang-2, another proangiogenic factor, was capable of overcoming resistance to therapies directed against the VEGF pathway in both the GL261 and human glioma stem cell xenograft mouse models (Figure 5 and Table 1) [127].